Characteristics and Outcomes of Adult Outpatients With Heart Failure and Improved or Recovered Ejection Fraction.

IMPORTANCE Heart failure (HF) guidelines recognize that a subset of patients with HF and preserved left ventricular ejection fraction (LVEF) previously had reduced LVEF but experienced improvement or recovery in LVEF. However, data on these patients are limited. OBJECTIVE To investigate the characteristics and outcomes of adult outpatients with HF and improved or recovered ejection fraction (HFrecEF). DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study (inception period, January 1, 2012, to April 30, 2012) with 3-year follow-up at cardiology clinics (including HF subspecialty) in an academic institution. The dates of the analysis were May 21, 2015, to August 10, 2015. Participants were all outpatients 18 years or older who received care for a verified diagnosis of HF not attributed to specific cardiomyopathies or other special causes during the inception period. EXPOSURES Type of HF at baseline, classified as HF with reduced ejection fraction (HFrEF) (defined as current LVEF ≤40%), HF with preserved ejection fraction (HFpEF) (defined as current and all previous LVEF reports >40%), and HF with recovered ejection fraction (HFrecEF) (defined as current LVEF >40% but any previously documented LVEF ≤40%). MAIN OUTCOMES AND MEASURES Mortality, hospitalization rates, and composite end points. RESULTS The study cohort comprised 2166 participants. Their median age was 65 years, 41.4% (896 of 2166) were female, 48.7% (1055 of 2166) were white and 45.2% (1368 of 2166) black, and 63.2% (1368 of 2166) had coronary artery disease. Preserved (>40%) LVEF at inception was present in 816 of 2166 (37.7%) patients. Of these patients, 350 of 2166 (16.2%) had previously reduced (≤40%) LVEF and were classified as having HFrecEF, whereas 466 of 2166 (21.5%) had no previous reduced LVEF and were classified as having HFpEF. The remaining 1350 (62.3%) patients were classified as having HFrEF. After 3 years, age and sex-adjusted mortality was 16.3% in patients with HFrEF, 13.2% in patients with HFpEF, and 4.8% in patients with HFrecEF (P < .001 vs HFrEF or HFpEF). Compared with patients with HFpEF and patients with HFrEF, patients with HFrecEF had fewer all-cause (adjusted rate ratio [RR] vs HFpEF, 0.71; 95% CI, 0.55-0.91; P = .007), cardiovascular (RR, 0.50; 95% CI, 0.35-0.71; P < .001), and HF-related (RR, 0.48; 95% CI, 0.30-0.76; P = .002) hospitalizations and were less likely to experience composite end points commonly used in clinical trials (death or cardiovascular hospitalization and death or HF hospitalization). CONCLUSIONS AND RELEVANCE Outpatients with HFrecEF have a different clinical course than patients with HFpEF and HFrEF, with lower mortality, less frequent hospitalizations, and fewer composite end points. These patients may need to be investigated separately in outcomes studies and clinical trials.

[1]  Sanjiv J. Shah,et al.  Letter by Psaty et al regarding article, "Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes". , 2015, Circulation.

[2]  B. French,et al.  Heart Failure With Recovered Ejection Fraction: Clinical Description, Biomarkers, and Outcomes , 2014, Circulation.

[3]  D. Kitzman,et al.  Heart failure with preserved ejection fraction: a heterogenous disorder with multifactorial pathophysiology. , 2014, Journal of the American College of Cardiology.

[4]  Sanjiv J. Shah,et al.  Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial , 2014, Circulation. Heart failure.

[5]  Michael A. Burke,et al.  Prevalence, clinical characteristics, and outcomes associated with eccentric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. , 2013, The American journal of cardiology.

[6]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[7]  C. Specchia,et al.  Adrenergic receptor gene polymorphism and left ventricular reverse remodelling after cardiac resynchronization therapy: preliminary results. , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  David D McManus,et al.  Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. , 2013, The American journal of medicine.

[9]  S. Solomon,et al.  The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). , 2013, Journal of the American College of Cardiology.

[10]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[11]  Shannon M. Dunlay,et al.  Longitudinal Changes in Ejection Fraction in Heart Failure Patients With Preserved and Reduced Ejection Fraction , 2012, Circulation. Heart failure.

[12]  J. McMurray,et al.  Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of Repeat Hospitalizations , 2012, Circulation.

[13]  Adrian F Hernandez,et al.  Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes , 2012, Circulation.

[14]  G. Barbati,et al.  How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?". , 2012, The American journal of cardiology.

[15]  C. O'connor,et al.  Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. , 2012, American heart journal.

[16]  Akshay S. Desai,et al.  Heart failure with recovered ejection fraction: a distinct clinical entity. , 2011, Journal of cardiac failure.

[17]  Serguei V. S. Pakhomov,et al.  Systolic and diastolic heart failure in the community. , 2006, JAMA.

[18]  Nancy M Albert,et al.  Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. , 2006, JAMA.

[19]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[20]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[21]  David L Hayes,et al.  Sustained Reverse Left Ventricular Structural Remodeling With Cardiac Resynchronization at One Year Is a Function of Etiology: Quantitative Doppler Echocardiographic Evidence From the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) , 2006, Circulation.

[22]  J. McMurray,et al.  Heart failure with preserved left ventricular systolic function: a hospital cohort study , 2005, Heart.

[23]  J. Gardin,et al.  Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study , 2002, Annals of Internal Medicine.

[24]  S. Anker,et al.  Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. , 2001, Journal of the American College of Cardiology.

[25]  H. Samady,et al.  Left ventricular inotropic reserve and right ventricular function predict increase of left ventricular ejection fraction after beta-blocker therapy in nonischemic cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[26]  A. Levine,et al.  Impact of left ventricular size on pharmacologic reverse remodeling in heart failure , 2000, Clinical cardiology.